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Aquaporins (AQPs), members of the water-channel protein family, are highly expressed in brain tissue
especially in astrocytic end-feet. They are important players for water hemostasis during development of
cytotoxic as well as vasogenic edema. Increased expression of AQPs is important in pathophysiology of
neurological diseases such as neuroinflammation and ischemia. Unfortunately, there are a few pharma-
cological inhibitors of AQP4 with several side effects limiting their translation as a drug for use in clinical
conditions. Another therapeutic approach is using antisense oligonucleotides (ASOs) to block AQP4 activ-
ity. These are short, synthetic, modified nucleic acids that bind RNA to modulate its function. However, they
cannot pass the blood brain barrier (BBB). To overcome this obstacle we designed a nanoparticulate system
made up of chitosan nanoparticles surface modified with PEG and conjugated with monoclonal anti trans-
ferrin receptor-1 antibody via streptavidin-biotin binding. The nanocarrier system could be targeted to the
transferrin receptor-1 at the brain endothelial capillaries through monoclonal antibodies. It is hypothesized
that the nanoparticles could pass the BBB via receptor mediated transcytosis and reach brain parenchyma.
Particle size, zeta potential, loading capacity and release profiles of nanoparticles were investigated. It was
observed that all types of chitosau (CS) nanoparticles had positive zeta potential values and nanoparti-
cle particle size distribution varied between 100 and 800 nm. The association efficiency of ASOs into the
nanoparticles was between 80–97% and the release profiles of the nanoparticles exhibited an initial burst
effect followed by a controlled release. The results showed that the designed chitosan based nanocarriers
could be a promising carrier system to transport nucleic acid based drugs to brain parenchyma.
1. Introduction
Several strategies exist for drug delivery to the brain. Inva-
sive techniques such as distruption of the blood brain barrier
(BBB) temporarily by injecting mannitol solution or direct drug
delivery into the brain were effective techniques but they are
associated with an increased risk of infection and high cost
(Garcia-Garcia et al. 2005). Chemical methods (lipidization)
(Misra et al. 2003), or biological methods like direct conjuga-
tion of drug molecules with antibodies (Pardridge 2002), have
shown interesting results but they also have some drawbacks.
Linking of a lipophilic moiety or a ligand to the drug can provide
a loss of therapeutic effect. Another promising strategy could be
to bind drugs to colloidal carriers. They are able to deliver drug
molecules to a specific site by coupling ligands to the surface
of the colloids which can be administered intravenously. Also
receptor mediated targeting of polymeric nanosystems provides
selective targeting to tissues.
Aquaporins (AQP) are a family of homologous water chan-
nel proteins, expressed in many epithelial and endothelial cell
types involved in fluid transport (Agre 1997; Agre and Kozono
2003; Verkman 2002). AQPs increase the plasma membrane
osmotic permeability by controlling the water flow to intra-and
extra-cellular areas (Agre et al. 2002). AQPs basic structure is
a homo-tetramer forming a central pore through which water,
cations, and gases such as CO2 flow. The major type of AQPs
in the brain is AQP4 which has the highest water permeability
coefficient (Amiry-Moghaddam and Ottersen 2003; Jung et al.
1994; Yang and Verkman 1997). AQPs, the predominant water
channel protein in normal brain tissue, is especially expressed
in astro-glial foot processes (Amiry-Moghaddam and Ottersen
2003; Haj-Yasein et al.; Nielsen et al. 1997). They have an impor-
tant role in water hemostasis as well as edema formation under
pathological conditions (Manley et al. 2000; Ribeiro Mde et al.
2006; Verkman et al. 2006). AQP4 knockout mice were shown
to have dramatically reduced brain edema (Manleyet al. 2000;
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Fig. 1: Scanning electron micrographs of (a) CS nanoparticles, (b) CS-PEG nanoparticles, (c) CS-PEG-BIO nanoparticles, and (d) schematic illustration of CS nanoparticle
preparation procedure.
Papadopoulos and Verkman 2007). It would be a great inno-
vation to prevent edema formation in the brain by inhibiting
AQP4 synthesis. As the brain swells inside the noncompliant
skull, intracranial pressure rises, causing brain ischemia, her-
niation and eventually death (Saadoun et al. 2002; Tait et al.
2008). AQP4 antagonists cannot be used in vivo as they are
toxic (Migliati et al. 2009; Yool et al.). Hence, a novel car-
rier nanoparticulate system was developed for AQP4 antisense
oligonucleotides in this study.
Antisense oligonucleotides (ASOs) are short, single-stranded,
about 15–25 nucleotide long synthetic molecules having com-
plementary sequences of targeted mRNA or pre-mRNA by
which the selective hybridization yields the inhibition of gene
expression. These molecules are promising molecules in the
treatment of diseases such as cancer, AIDS, etc. However, major
problems in using such molecules in the treatment of diseases
are lack of stability and poor penetration into the cell, thus a spe-
cific carrier is needed (Agrawal and Iyer 1997; Dias and Stein
2002a; Dias and Stein 2002b; Jason et al. 2004; Lee and Roth
2003; Lochmann et al. 2004). Enzymatic instability problems
of oligonucleotides could be partially solved by chemical mod-
ifications like phoshorothioate binding (Campbell et al. 1990;
Crooke 2000).
In this context, we used an oligonucleotide (5 /56-
FAM/T*C*A*T*A*C*G*G*A*A*G*A*C*A*A*T*A*C*C*T
*C-3) that was designed for the inhibition of AQP4’s membrane
linkage side subunit synthesis. Protection of ASOs from exo-
and endo- nuclease activity is managed by means of phospho-
rothioate modification (Monia et al. 1996). As these kind of
drugs are encapsulated into a polymer based nanoparticulate
systems such as Chitosau (CS), their stability in blood would
be enhanced. However, conventional polymeric systems are
removed from the bloodstream by reticulo-endothelial system
and this leads to an important reduction in pharmaceutical
efficiency (Tosi et al. 2008). When nanoparticulate drug
carrier systems are coated with a hydrophilic polymer such
as polyethylene glycol (PEG), system stays longer in blood
circulation and also pharmacokinetic properties are optimized
(Torchilin et al. 2001). A conjugation of a nanoparticulate
carrier system to a monoclonal antibody is needed to overcome
the blood-brain barrier (BBB). This is accomplished via
targeting them to the transferrin receptors located in the BBB,
specifically on endothelial lining (Aktas et al. 2005; Olivier
et al. 2002; Ulbrich et al. 2009).
The purpose of this study was to evaluate particle size, zeta
potential, morphological properties, encapsulation efficiencies
and release profiles of chitosan nanocarriers loaded with a
phosphorothioate modified antisense oligonucleotide which
could be a promising carrier system to transport nucleic acid
based drugs to brain parenchyma in the case of edema and other
brain diseases.
2. Investigations and results
2.1. Nanoparticle characterization
All types of CS nanoparticles were prepared according to the
ionic gelation procedure. Nanoparticles were formed via the
interactions between the positive amino groups of CS and neg-
ative anionic groups of tripolyphosphate (TPP). Nanoparticle
surface was modified with PEG to provide enhanced blood resi-
dence time. To prepare “stealth” nanoparticles, the polymer (CS)
was PEGylated before nanoparticle preparation.
SEM images of blank and loaded CS, CS-PEG, and CS-PEG-
BIO nanoparticles are shown in Fig. 1a-c, respectively. The
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Table 1: Characteristics (zeta potential and particle size) of
blank and 5 g ASO loaded nanoparticles
Polymer Zeta potential (mV) Particle size (nm)
Blank Loaded Blank Loaded
CS 26 ± 2 23 ± 6 267 ± 14 338 ± 9
CS-PEG 18 ± 2 15 ± 3 116 ± 4 170 ± 9
CS-PEG-BIO 15 ± 3 14 ± 4 612 ± 6 671 ± 7
CS-PEG-BIO/MAb 18 ± 1 16 ± 1 686 ± 9 784 ± 5
Table 2: Association efficiency values (%) with the change of
polymer, the amount of ASO loaded, and the type of
the solution that ASO added
ASO amount The solution that the ASO added into
Polymer solution TPP solution
5 g 10 g 15 g 5 g 10 g 15 g
CS 98 ± 2 97 ± 1 92 ± 3 90 ± 2 92 ± 4 88 ± 2
CS-PEG 97 ± 2 95 ± 2 90 ± 3 89 ± 5 90 ± 4 82 ± 4
CS-PEG-BIO 93 ± 2 90 ± 3 87 ± 3 83 ± 4 85 ± 4 80 ± 4
Fig. 2: In vitro release profiles of ASO from CS, CS-PEG, and CS-PEG-BIO
nanoparticles (37 ◦C, pH 7.4).
particles showed a dense and generally spherical structure. Par-
ticle size and zeta potential of nanoparticles are given in Table 1.
2.2. ASO Encapsulation
There was a significant increase in the ASO encapsulation effi-
ciency for the conjugated nanoparticles as compared with the
non-conjugated nanoparticles (Table 2). Also, there was a signif-
icant increase of association efficiency when the oligonucleotide
molecule was firstly added into the polymer solution during the
manufacturing process.
2.3. In vitro release of ASO from nanoparticles
The release profiles of oligonucleotide from the different types
of CS nanoparticles in phosphate buffered saline (PBS) at a pH
of 7.4 are shown Fig. 2. A fast initial release for all types of
polymers was determined. A slow release was observed after 6 h
and the profiles reached plateau values after 24 h.
The percentage of ASO released from the system was increased
by modification of the polymer. CS-PEG-BIO nanoparticles
exhibited higher amounts of release than other derivatives. The
percentage of the released drug was enhanced by the increasing
hydrophobic characteristic of modified polymers.
Fig. 3: In vitro release profiles of ASO from CS-PEG-BIO nanoparticles with
different manufacturing processes (with the change of the solution ASO
added) (37 ◦C, pH 7.4).
One more explored parameter that may affect the release pro-
files was the addition of ASO to TPP solution or to the polymer
solution. Higher concentration of ASO was obtained in release
medium when ASO is added into the TPP solution even they
have lower association efficiencies and vice versa for the addi-
tion into the polymer solution.
3. Discussion
AQPs have important roles in brain water hemostasis under
physiological conditions. During disease states like ischemia,
trauma or brain tumor, they can lead to brain edema formation
through AQP4. Up to date there is no specific anti edema treat-
ment. Inhibition of AQP4 channels either with non-selective
inhibitors or knocking down the gene and expression in trans-
genic animal models demonstrated promising results. Hence,
new therapeutic methods that will specifically inhibit AQP4
activity could be used in clinical conditions.
ASOs are short, synthetic, modified nucleic acids that bind RNA
and modulate its function by either gene silencing or regula-
tion of RNA metabolism. They should have enough half-life
within tissues, appropriate biodistribution, and efficient uptake
in order to be effective as therapeutics. Modification of the phos-
phate backbone can increase the tissue half-life of ASOs. One
of the mostly used modifications is phosphorothioate modifica-
tion, which is the substitution of a non-bridging oxygen in the
phosphate backbone with a sulfur atom. Phosphorothioate mod-
ification greatly improves the stability of ASOs and still allows
cleavage by RNAse so that the antisense can reach the desired
target without degradation.
One of the obstacles during treatment of neurological and psy-
chiatric diseases is the penetration of therapeutics to the brain
tissue. BBB is the main limitation and only allows penetration
of a limited number of substances and drugs. However, there are
several specialized transport systems located in the endothelia
of the BBB such as receptor mediated transcytosis (Abbott et al.
2006). Transferrin receptor is used for this purpose.
In this study, we combined novel brain targeted nanoparticles
with ASO designed against AQP4 binding site to syntrophin
located on the dystrophino-glycan complex of astrocytic mem-
branes. Through using this type of ASO, we have the advantage
of loss of function rather than knockdown.
CS is a natural polysaccharide that allows the production of
biocompatible and biodegradable drug delivery systems. Water
solubility and positive charge of chitosan is extremely impor-
tant in order to enable an interaction of negatively charged
polymers and macromolecules with polyanions in an aqueous
environment (Prabaharan 2008). Also the endothelial cells in the
BBB have negative surface charge so that the positive surface
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charge of chitosan nanoparticles could increase the possibility
of the interaction between the nanoparticles and brain vascu-
lar endothelium. On the other hand, mild conditions of chitosan
nanoparticle preparation procedure through aqueous solubility
of polymer provides enhanced stability of encapsulated drug.
Blank and ASO-loaded CS, CS-PEG, and CS-PEG-BIO
nanoparticles formed spontaneously upon incorporation of the
counter anion TPP into the corresponding CS, CS-PEG, and
CS-PEG-BIO polymer solutions. Nanoparticles were formed as
a result of the ionic interactions between the negative TPP and
the positively charged amino groups of CS. The ratio of CS/TPP
was established according to the preliminary studies.
ASO loading did not affect the general morphological properties
of nanoparticles. Thus, it can be mentioned that both loaded and
blank particles have spherical shape and show uniformity in
particle size distribution.
It was observed that CS-PEG nanoparticles were smaller than
CS nanoparticles. This may be explained by the colloid stabiliza-
tion exerted by the PEG. On the other hand, when the surface of
nanoparticles were modified with PEG-BIO or PEG-BIO/MAb,
a significant increase in nanoparticle size was observed. This
may be attributed to an increase in the hydrophobicity of the
surface of the nanoparticles leading to aggregation due to pres-
ence of bulky groups on the surface. As shown in Table 1,
blank nanoparticles displayed a zeta potential in the range of
26–18 mV. The addition of the negatively charged ASO resulted
in a significant decrease in the zeta potential of the nanoparticles
to the range 23–16 mV.
Under optimal conditions, higher values of ASO and chitosan
were encapsulated inside the nanoparticles due to ionic inter-
actions between positively charged chitosan and negatively
charged oligonucleotide molecules. There were several factors
which could affect the encapsulation of the oligonucleotide in
the CS nanoparticles, such as CS/TPP ratio, auxiliary molecules,
and interaction between the ASO and CS. Also blocking the
ionic interaction between chitosan and ASO by modifying the
groups would cause an increase in the interaction and the asso-
ciation as well. In this study, the AE% could be correlated with
the surface modification of the CS. Also, the type of the solu-
tion (polymer or crosslinker) to which ASO were added was
also important.
A fast initial release from all type of polymers suggests that
some amount of the ASO could be located onto the surface of
the nanoparticles to result in a burst release. After 6 h a slow
release due to degradation of nanoparticles was determined.
The higher release amount when ASO was added into the TPP
solution instead of into the polymer solution could be asso-
ciated with the strong ionic interaction between chitosan and
oligonucleotide molecules.
As a consequence of these results, this system could be regarded
as a preferable pharmaceutical carrier system for nucleic acid
based drug molecules. CS-PEG-BIO derivative of CS was the
most suitable polymer for our purpose in the sense of higher EA
and closer to intended release profile. The BIO modification was
also provided to attach the Ab via streptavidin-biotin linkage and
increased the preferability of the derivative.
This novel nanocarrier system demontrated a capacity for the
association of the antisense oligonucleotide molecule. Due to
the high interaction ability of the chitosan with the negatively
charged oligonucleotide molecule and the release profiles sug-
gested this oligonucleotide carrier system as promising and
could be used as a drug carrier for nucleic acid based ther-
apeutics like plasmid DNA, siRNA, etc. as well as antisense
oligonucleotides. In vivo experiments are needed to prove the
effectiveness and safety of this nanoparticulate carrier system
and further studies are needed to exhibit the efficacy of the
system for penetration through the BBB.
4. Experimental
4.1. Materials
Chitosan (Protasan Cl 113, Mw 150 kD, deacetylation degree: 75- 90%)
was purchased from FMC Biopolymers (Norway). Pentasodium TPP,
streptavidin, maleimidobenzoyl N-hydroxy-succinimide ester (MBS) were
purchased from Sigma-Aldrich and Traut’s Reagent (2-iminothiolane) was
purchased from Thermo Fisher Scientific Inc, Pierce (USA). Functional-
grade purified anti-mouse CD71 (transferrin receptor) (clone: R17217,
catalog no: 16–0711) antibody was received from eBioscience (USA). Ace-
tonitrile was HPLC grade, triethylamine (TEA) was synthesis grade and
glacial acetic acid was analytical grade and they were all purchased from
Merck KGaA (Darmstadt, Germany). Water was purified to 18.2 .cm of
electrical resistivity in-house using a Millipore Simplicity® UV system
(USA). Oligonucleotide molecule was synthesized and purchased from
IDT-DNA (USA). The antisense oligonucleotide was synthesized with
phosphorothioate bond modification to increase molecule stability against
nucleases and prolong plasma residence time (Campbellet al. 1990). Addi-
tionally, the molecule was tagged with a fluorescence emitting 6-FAM group.
4.2. Methods
4.2.1. Synthesis of CS-PEG
CS · HCl (100 mg, 0.50 mmol) was dissolved in H2O (14.3 ml). MeO-
PEG-OCH2CO2H has been synthesized from a commercially available
MeO-PEG-OH according to known procedures (Royer and Anantharma-
iah 1979). MeO-PEG-OCH2CO2H (17.8 mg, 3.47 mol, Mn 5114)
and N-hydroxysuccinimide (NHS) (2.03 mg, 0.018 mmol) were
then added to the solution. Finally, N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDC · HCl) (27.1 mg, 0.141 mmol) was
added in portions due to its instability. The resulting solution was stirred
at room temperature for 22 h and then was ultrafiltered (Amicon, YM30)
and lyophilized to yield CS-g-PEG (CS-PEG) as white foam (105 mg). The
degree of PEGylation of this sample was 0.6% as determined by 1H NMR
(2% DCl in D2O) (Fernandez-Megia et al. 2007; Novoa-Carballal et al.
2013).
4.2.2. Synthesis of CS-PEG-BIO
CS-PEG-BIO was synthesized following the same procedure as
described above for CS-PEG from CS · HCl (100 mg, 0.50 mmol), HO2C-
PEG-biotin (14.6 mg, 3.65 mol, Mn 4030) (Fernandez-Megiaet al. 2007),
NHS (1.87 mg, 0.016 mmol), and EDC · HCl (27.0 mg, 0.141 mmol).
After ultrafiltration and lyophilization CS-PEG-BIO was obtained as white
foam (110 mg). The degree of PEGylation of this sample was 0.6% as
determined by 1H NMR (2% DCl in D2O) (Fernandez-Megiaet al. 2007;
Novoa-Carballalet al. 2013).
4.2.3. Preparation of chitosan and surface-modified chitosan
nanoparticles
CS, CS-PEG, or CS-PEG-BIO nanoparticles were prepared by ionic gela-
tion of CS, CS-PEG, or CS-PEG-BIO with TPP according to a procedure
previously developed for the preparation of CS nanoparticles (Calvo
et al. 1997). Preliminary experiments were performed in order to iden-
tify the optimal concentrations of CS and TPP for nanoparticle formation.
Practically, CS nanoparticles were formed upon dropwise addition of
1 mL TPP aqueous solution (0.4 mg/mL) to 1 mL of CS aqueous solu-
tion (1.75 mg/mL). Likewise, CS-PEG and CS-PEG-BIO (1 mg/mL each)
nanoparticles were prepared by dropwise addition of 0.4 mL TPP aqueous
solution (0.84 mg/mL) to 1 mL of each of the corresponding aqueous poly-
mer solutions. These solutions were then stirred under magnetic stirring
at medium speed and room temperature. Nanoparticles were isolated by
ultracentrifugation (10,000 rpm, 4 ◦C, 60 min) and resuspended in water by
manual shaking.
4.2.4. Preparation of TfRMAb-conjugated nanoparticles
The SA/TfRMAb conjugates were prepared according to the proce-
dure described by Karatas et al. (2009). Briefly, 7 mg of SA was dissolved
in 250 L 0.1 M EDTA (Solution I). Traut’s reagent solution (100 L,
4 mg/mL) and borate buffer (1.9 mL) were mixed and stirred for 5 min
on magnetic stirrer at room temperature (Solution II). Equal volumes of
Solution I and II were mixed and stirred for 90 min. To transform some
of the amino groups into maleimide groups, antibody solution (100 L,
1 mg/mL) was mixed with m-maleimidobenzoyl-N-hydroxysuccinimide
solution (5 L, 5 mg/mL in dimethylformamide) 12.5 L of streptavidin
solution and 12.5 L of antibody solution were added to CS-PEG-
BIO nanoparticle suspension (500 L); this suspension was vortexed for
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30 s and incubated for 30 min at room temperature. Loading of ASO was
performed in the same conditions as for TfRMAb-free chitosan nanoparti-
cles.
4.2.5. ASO entrapment in chitosan–TPP nanoparticles
Different amounts of ASO (5, 10, 15 g) were dissolved in ultrapure water
for the association of ASO with the chitosan-TPP nanoparticles. ASO solu-
tion was added into crosslinker solution or polymer solution considering
the final concentration of these solutions must be remained unchanged.
Crosslinker (TPP) solution was added onto the polymer solution under
constant magnetic stirring at room temperature. The particles were then
incubated at room temperature for 10 min before use or further analysis.
4.2.6. Characterization of nanoparticles
Measurements of the size and zeta potential of the nanoparticles were
performed in triplicate by photon correlation spectroscopy and laser
Doppler anemometry, respectively, using a Zetasizer Nanosystems 3000
HS (Malvern Instruments, UK). The size measurements were performed
at 25 ◦C at a 90 ◦ scattering angle, and each measurement was recorded for
180 s.
4.2.7. Quantitative analysis of ASO
For the quantitative analysis of ASO, an HPLC method was developed
and validated. An Agilent Technologies 1100 Series liquid chromatograph
with a degasser (Tokyo, Japan), a quaternary pump, a thermostatted auto-
sampler, a thermostatted column compartment, and a fluorescent detector
FLD (Germany) was used. For data processing ChemStation (Agilent Tech-
nologies, USA) software was used. The column (Nucleodur C18, 5 m, 250 x
4.6 mm) was purchased from Higgins Analytical Inc. (California, USA). The
flow rate of mobile phase was 1.0 mL/min at isocratic conditions. The injec-
tion volume was 20 L, the column thermostat temperature was maintained
at 55 ◦C and the detector wavelength was set at 495 nm for the excitation
and 520 nm for emission wavelengths. The mobile phase comprised 0.1 M
triethylammonium acetate (TEAA), pH 7.0, and acetonitrile (70:30, V/V).
4.2.8. Determination of ASO loading efficiency
The loading capacity of ASO (%) entrapped into the chitosan nanoparticles
was obtained from the determination of free ASO concentration in the super-
natant recovered after particle centrifugation (10,000 rpm at 4 ◦C for 1 h).
Association efficiency was the percentage of entrapped ASO, (difference
between the total amount of ASO added for the nanoparticles preparation
and the amount of non-entrapped ASO remaining in supernatant after cen-
trifugation) to the total amount of ASO added. The amount of free peptide
was then measured in the clear supernatant by RP-HPLC method mentioned.
The association efficiency (AE) was calculated according to the following
equation:
%AE = 100 × (total peptide amount − free peptide amount)/
total peptide amount.
4.2.9. Evaluation of in vitro ASO release from
CS-PEG-BIO/SA-TfRMAb nanoparticles
The nanoparticles were collected by centrifugation at 10,000 rpm for 1 h
and every batch of nanoparticles were then resuspanded in 500 L of PBS,
pH 7.4, at 37 ◦C to quantify the released amount of ASO. Nanoparticle
suspension was immobilized on a shaking water bath, the supernatant was
isolated by centrifugation at 10,000 rpm for 20 min at 4 ◦C at varying time
points, and the amount of ASO released was measured by RP-HPLC as
described earlier.
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